People Winette van der Graaf

Contact

Winette van der Graaf MD PhD

+31 (0)24 366 63 70
contact

Winette van der Graaf full professor

Winette van der Graaf is Professor of Translational and Personalised Oncology at Radboud University. She trained and did her PhD on “Circumvention of Multidrug resistance in Cancer”.

read more

Winette van der Graaf full professor

Winette van der Graaf is Professor of Translational and Personalised Oncology at Radboud University and was appointed at the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital in Amsterdam October 2018. She trained and did her PhD on “Circumvention of Multidrug resistance in Cancer” at the University of Groningen. She was member of staff at the department of medical oncology, UMC Groningen until 2007 when she moved to Radboudumc Nijmegen where she was appointed as full professor. She was head of department of Medical Oncology (2010-2015), moved to London and was full professor at the Institute of Cancer Research, teamleader clinical and translational sarcoma research, and worked at the Royal Marsden Hospital. She has been board member of the Dutch Society of Medical Oncology (2007-13), SONCOS (the Dutch multidisciplinary Society of Medical Oncologists, Radiation Oncologists and Surgical Oncologists; 2009-13), was national director of training for Medical Oncologists (2008-11), headed the EORTC Sarcoma group (2007-2010) and is board member of the EORTC (2015-). She initiated the Radboud platform for AYA cancer patients, and in 2013 the national AYA programme. She was the PI on the PALETTE trial which led to the global registration of pazopanib in advanced soft tissue sarcomas (Lancet 2012). She is active in many clinical trials, translational research projects (genetics, imaging) and co-leads research projects on quality of life in sarcoma and AYA patients.

Translational Medical Oncology

This research line aims at bringing preclinical findings from the lab to the clinic and vice versa. In cell lines, preclinical mouse models of different tumor types and tissue we look at new targets of therapy, and efficacy of combination therapy. Preclinical testing is done a.o. with SPECT and PET imaging. Vice versa, unexplained observations from the clinic are investigated in the lab. In 2008 Prof Wim Oyen and I raised the Radboud Translational Oncology Platform (RTOP) to optimize collaboration and visualize translational research in our UMC to e.g. partners from industry. This led to the start of the Roche‐ Dutch Imaging Hub in 2010, which has already generated many (pre)clinical translational research projects.

Sarcoma Research

In this line we aim to search for innovative targets of therapy, and look at side and late effects of treatment in sarcoma patients. In tumor material, linked to clinical outcome, we search for prognostics and predictive factors of therapy. In preclinical mouse models we evaluate effects of new targeted and conventional chemotherapy.

Psychosocial and Age related Oncology

Here we aim at findings factors of vulnerability of special patients groups or their family members. In 2009 Prof Judith Prins and I raised the so‐called Gammaraad to better define the final goal of all psychosocial research (which is defined as patient empowerment).
 
AYA research is performed within the frame work of the AYA platform, which I raised in 2009. This focuses on age related aspects of side effects and outcome of therapy. This AYA research has both psychosocial and basic research aspects.
  • 1992 Board Certification as internist 
  • 1992 Staff member of the Division of Medical Oncology, Department of Internal Medicine, University Medical Center Groningen 
  • 1993 Registration as Medical Oncologist 
  • 1993 Ph.D."Circumvention of multidrug resistance in cancer", University of Groningen (RUG) 
  • 2000-2007 Associate Professsor of Medical Oncology University of Groningen 
  • 2007-2010 Full Professor of Translational Medical Oncology Radboud University Nijmegen 
  • 2010-present Full professor of Medical Oncology, Head of Department of Medical Oncology 
  • 2007-present Director of Medical Oncology fellowship training program, Nijmegen 
  • 2007-present Board position of EORTC Soft Tissue and Bone Sarcoma Group(STBSG), chairman 
  • 2012-2014 2007-2013 Board position (secretary; vice-chair) Dutch Society of Medical Oncology 
  • 2008-2011 Chairman of the Section Medical Oncology of the Dutch Society for Internal Medicine (NIV) , member of Concilium 
  • 2009-2013 Board position of SONCOS, a national multidisciplinary Society of Medical Oncologists, Radiation Oncologists and Surgical Oncologists in The Netherlands 
  • 2008-present Initiator and Chairman of Adolescent and Young Adult (AYA) Cancer platform Radboud University Nijmegen Medical Center 
  • 2008-present: Chairperson Radboud Sarcoma Research Group 
  • 2009-present (Founding)member World Sarcoma Network 
  • 2012- present Member Signaling Committee Dutch Cancer Society (KWF) 2012- present Member Scientific Advisory Committee SPAEN (Sarcoma Patients EuroNet Association) 
  • 2012-present Member International Rare Cancer Initiative (IRCI)
  • 2013-present Founder and chairperson of Dutch AYA cancer network, 
  • 2008-present Principal investigator Radboud University Medical Center
  • 2013-present Principal clinician at Radboud University Nijmegen Medical Center (award for innovations in healthcare)

Personal prizes & awards national & international

  • 2001: Annual Research Award Young Talent of the University Hospital & the Faculty of Medical Sciences, University of Groningen
  • 2016: National AYA Award (for Adolescents and Young Cancer patients)

Additional functions

  • Member of the EORTC board, chair of Translational research Division
  • Chair of the Dutch Sarcoma Study Group
read more

Additional functions

  • Member of the EORTC board, chair of Translational research Division
  • Chair of the Dutch Sarcoma Study Group
  • Honorary appointment at The Institute of Cancer Research and the Royal Marsden Hospital London
  • Appointment at the Antoni Van Leeuwenhoek Hospital/Netherlands Cancer Institute

Field of study

Medical Oncology

Radboud Institute for Health Sciences

Ideally, every procedure in clinical practice and public health should take place based on proof, instead of intuition or 'experience'. Our aim is to innovate and personalize healthcare and public health. read more